Overview

PET Trial to Evaluate Target Occupancy of CVL-231 on Brain Receptors Following Oral Dosing

Status:
Recruiting
Trial end date:
2022-05-01
Target enrollment:
Participant gender:
Summary
PET Trial to Evaluate Target Occupancy of CVL-231 at Muscarinic Receptors Type 4 in Brain Following Oral Dosing
Phase:
Phase 1
Details
Lead Sponsor:
Cerevel Therapeutics, LLC